

CLAIM AMENDMENTS

This listing of claims will replace all prior versions and listings of claims in the application:

1-38. (canceled)

39. (currently amended) A method of treating small cell lung cancer or neuroblastoma in a subject which comprises administering an amount of a composition comprising an α -(2-8)-polysialic acid-carrier conjugate and adjuvant in amount effective to ameliorate said small cell lung cancer or neuroblastoma, wherein the α -(2- 8)-polysialic acid-carrier conjugate comprises one or more α -(2- 8)-polysialic acid polymers covalently linked to an immunogenic carrier, and wherein the median number ~~of~~ of sialic acid units in each of the polymers is at least about 10.

40. (original) The method of Claim 39 wherein the α -(2-8)-polysialic acid polymer is modified to increase immunogenicity.

41. (original) The method of Claim 40 wherein the modified α -(2-8)-polysialic acid polymer is N-propionylated α -(2-8)-polysialic acid.

42. (original) The method of Claim 39 wherein the α -(2-8)-polysialic acid-carrier conjugate consists essentially of one or more α -(2-8)-polysialic acid polymers

covalently linked to an immunogenic carrier, wherein the median number of sialic acid units in each of the polymers is at least about 10.

43. (original) The method of Claim 39 wherein the median number of sialic acid units in each of the polymers is at least about 50, or wherein each of the polymers has an average molecular weight of at least about 10,000.

44. (currently amended) The method of Claim 39 wherein the immunogenic carrier is keyhole limpet hemocyanin (KLH), ~~an immunogenic derivative of KLH, bovine serum albumin (BSA), an immunogenic derivative of BSA, or a promiscuous class II activating polypeptide, or an immunogenic derivative of a promiscuous class II activating polypeptide.~~

45. (original) The method of Claim 39 wherein the immunogenic carrier is KLH.

46. (original) The method of Claim 45 wherein the molar ratio of polysialic acid to KLH in the conjugate is from about 25 to about 1000.

47. (original) The method of Claim 45 wherein the molar ratio of polysialic acid to KLH in the conjugate is about 200.

48. (currently amended) The method of Claim 39 wherein said adjuvant comprises alum, a saponin, ~~a semi-synthetic saponin-like molecule~~, CpG, granulocyte-macrophage colony-stimulating factor (GM-CSF), Freund's complete adjuvant, Freund's incomplete adjuvant or an oil-in-water emulsion.

49. (original) The method of Claim 39 wherein said adjuvant is a saponin in an amount from about 1 µg to about 2000 µg.

50. (original) The method of Claim 39 wherein said saponin is QS-21 or GPI 0100.

51. (original) The method of Claim 50 wherein QS-21 is in an amount from about 50 µg to about 500 µg.

52. (original) The method of Claim 51 wherein the amount of QS-21 is about 100 µg.

53. (original) The method of Claim 50 wherein GPI 0100 is in an amount from about 100 µg to about 2000 µg.

54. (original) The method of Claim 53 wherein the amount of GPI 0100 is from about 500 µg to about 1000 µg.

55. (original) The method of Claim 39 wherein the amount of polysialic acid of said conjugate is from about 1 μg to about 1000 μg .

56. (original) The method of Claim 39 wherein the amount of polysialic acid of said conjugate is about 30 μg .

57. (original) The method of Claim 39 wherein said composition comprises an α -(2-8)-polysialic acid-KLH conjugate and QS-21 wherein the α -(2-8)-polysialic acid-carrier conjugate consists essentially of α -(2-8)-polysialic acid polymers covalently linked to KLH, and wherein the median number of sialic acid units in each of the polymers is 14 or greater.

58. (original) The method of Claim '39, wherein the composition is administered after the subject has undergone primary treatment for the small cell lung cancer or neuroblastoma.

59. (original) The method of Claim 39, wherein the composition is administered to treat metastasis of said small cell lung cancer or neuroblastoma.

60-81. (canceled)